About: Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 14 October 2010

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в жовтні 2010 (uk) scientific article published on 14 October 2010 (en) artículu científicu espublizáu n'ochobre de 2010 (ast)
publication date	wds:Q85191655-14520FD7-2836-4144-AD7A-5B4190B009A1
publication date	2010-10-14 00:00:00Z (xsd:dateTime)
exact match	wds:Q85191655-99BE2795-2B7D-4B56-B3E3-43E778A04841
exact match	https://scigraph.springernature.com/pub.10.1007/s10549-010-1187-2
author name string	wds:Q85191655-32A84644-3451-4782-BD3D-5401EA9D01C3 wds:Q85191655-994439DA-E053-4179-84B8-3B172281D3A8 wds:Q85191655-9EFD72BC-B3C8-4838-A2AF-485806A9282C wds:Q85191655-B2B06085-9B88-4399-B61D-2FC3D9C10C70 wds:Q85191655-FA0301E7-385B-478B-BC11-5C0E2E482CCD
author name string	Jose Iglesias Nicholas Robert Lea Krekow Alicia Clawson Chris Stokoe
rdfs:label	Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study (en) Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study (nl)
skos:prefLabel	Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study (en) Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study (nl)
name	Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study (en) Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study (nl)
author	wds:Q85191655-DA1C7977-47A0-4E58-847D-5531EDDED6ED
author	Joyce O'Shaughnessy
title	wds:Q85191655-F80CEF94-5943-4BBB-AED7-508DF2E142EA
title	Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study (en)
page(s)	wds:Q85191655-B2ACFA21-DAE6-4F40-A028-DE467AD075F5
page(s)	115-120
instance of	wds:Q85191655-5B0CC6BE-F3DB-4C22-A2E6-26456CAC1984
instance of	scholarly article
main subject	wds:Q85191655-A61E619F-DF63-414D-BC78-1B27F87CCDFB
main subject	wd:Q18936
PubMed ID	wds:Q85191655-C35B3206-D97C-437C-8BFA-DAF13AF82FA6
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/20945091
PubMed ID	20945091
published in	wds:Q85191655-F07D156F-53D7-4E36-982C-DB21D6BE84F0
published in	Breast Cancer Research and Treatment
issue	wds:Q85191655-3FB5C321-4049-44F9-81A8-B5DBDF136207
volume	wds:Q85191655-F6595AFB-0B75-4D8E-809D-EABF1A05535F
issue	1
volume	125
DOI	wds:Q85191655-E86650B6-8DA4-43DE-8600-C4ED381A6ED0
DOI	http://dx.doi.org/10.1007/S10549-010-1187-2
DOI	10.1007/S10549-010-1187-2
Dimensions Publication ID	wds:Q85191655-700ED6C9-F7F5-424C-A18D-C7D411EC2D22
Dimensions Publication ID	1008334081
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q85191655
is cites work of	The mesenchymal tumor microenvironment: a drug-resistant niche Taxanes for the treatment of metastatic breast cancer Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer. Taxane anticancer agents: a patent perspective Clinical Translation of Nanomedicine. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer
is cites work of	wds:Q35128729-3C29E98D-F219-4BA6-87B7-0B5328795A01 wds:Q34965672-49CBF217-96A1-4C32-AAC0-82000E1340AB wds:Q36364762-A8391707-01C1-4EC3-8A21-92F35398D200 wds:Q37197579-9AF83088-CB38-4B8A-9EAC-AE98EC3A0672 wds:Q35623087-A927B175-917B-485A-B1C7-9E5B0179A923 wds:Q37087888-43798292-268B-4AEB-9C61-2CEF0EA3F3B3 wds:Q30355939-323DF2CA-CFB2-472E-97EA-64CBC87947AD wds:Q36187755-FF86BDDA-A78E-4999-848E-DE5053B3B80D

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software